Zennova Pharmaceuticals Group, a contract manufacturing organization (CMO) with operations in New Jersey, US, and Chengdu, China, has completed Phase 1 construction on a manufacturing site and R&D center in Chengdu, Sichuan province. The 300,000 square foot facility includes a multi-dosage formulation center, warehousing, and administrative buildings, marking a significant expansion for the company.
Facility and Capabilities
Zennova is establishing manufacturing capabilities that meet the stringent standards of the US FDA, EU, and China’s NMPA, positioning itself for international markets. The company specializes in the production of high-barrier complex drugs, including anti-tumor medications, sterile eye drops, and central nervous system drugs. This strategic investment in Chengdu aims to enhance Zennova’s global footprint and serve a broader client base.
Future Expansion Plans
The completion of Phase 1 is just the beginning, as the second phase of construction will add an additional 500,000 square feet to the site. This expansion will further strengthen Zennova’s capacity to meet the growing demand for high-quality pharmaceutical manufacturing and R&D services globally.-Fineline Info & Tech
